Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand | BMC Cancer | Full Text

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand | BMC Cancer | Full Text

Development and validation of a predictive model for estimating EGFR mutation probabilities in patients with non-squamous non-small cell lung cancer in New Zealand

Targeted treatment with Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) is superior to systemic chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR gene mutations. Dete...

Authors:Phyu Sin Aye, Sandar Tin Tin, Mark James McKeage, Prashannata Khwaounjoo, Alana Cavadino and J. Mark Elwood

Citation:BMC Cancer 2020 20:658

Content type:Research article

 

Published on: 14 July 2020

• ViewFull Text
 
• ViewPDF